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Patent ductus arteriosus (PDA) is the most common cardiovascular abnormality 
during infancy, increases mortality risk 8-fold, and is linked to chronic lung disease, 
pulmonary hypertension, and congestive heart failure.1 Early pharmacological treatment 
is a commonly employed to close PDA in the first weeks of life, but 35-50% infants fail 
or have contraindications to drug therapy (failed early treatment). Considerable 
uncertainty exists regarding best treatment for the cohort of infants following failed early 
treatment who continue to have clinical and hemodynamic perturbations potentially 
attributable to the ductus.2 Traditionally, surgery was used following failed early 
treatment, with some evidence, albeit limited, suggestive of lower mortality and 
improved outcomes following surgical closure.3 Over the past decade, associations 
between surgical PDA ligation and adverse outcomes within large cohort studies led to 
a secular trend away from definitive ductal closure.4  
Currently, most health care providers have adopted an observational (non-
intervention) approach to the PDA following failed early treatment. This approach avoids 
(or at least delays) procedure-related complications, but prolongs the duration of PDA 
exposure while the clinician watchfully waits for a spontaneous ductal closure.  
However, consensus on how long observation can be tried is lacking, with some 
evidence of greater risks following prolonged exposure.5 The American Academy of 
Pediatrics notes the urgent need for clinical trials to identify the optimal treatment 
strategy for this subgroup of infants, but lack of equipoise between the surgical and 
watchful waiting approaches’ precluded the conduct of such trials.2  In the absence of 
clear evidence, the fundamental question of whether closure versus non-closure of the 
ductus following failed early treatment improves important longer-term patient outcomes 
remains unanswered. But what if there were an alternative, minimally-invasive approach 
to achieve definitive ductal closure? Might it lead to improved outcomes in infants 
deemed to be at high-risk for PDA-attributable complications? 
On January, 11th, 2019, the US Food and Drug Administration approved the  
Amplatzer Piccolo™ Occluder (or Amplatzer duct occlude II additional sizes, or ADO-II 
AS).6 The device is designed for ductal closure among infants weighing >700 grams 
with a postnatal age ≥3 days. While the device has been available in Europe for over 5 
years, U.S. health care providers now have this non-surgical alternative to achieve 
definitive PDA closure. Design and technique modifications are attractive, including less 
bulky retention disks, low profile delivery system via 4 French catheters, and device 
delivery by venous-only cannulation. Promising data on technical feasibility, short-term 
safety, and of potential short and longer-term improvements in respiratory status (days 
on mechanical ventilation, need for diuretic therapy) from single-center, observational 
studies, has led to growing interest in percutaneous closure among lower weight infants.  
In fact, catheter-based closure has surgery as the primary technique for definitive PDA 
closure among preterm infants at some U.S centers.7   
While catheter-based PDA closure provides the neonatal community with an 
opportunity to advance our understanding of optimal treatment practices, lack of 
comparisons with alternative treatments (e.g. conservative therapy) obscures 
risk/benefit profiles, reinforcing the need for well-designed, multicenter, randomized 
controlled trials (RCTs).  Prior to the design and execution of such trials, a number of 
barriers to study conduct and execution must be overcome. At present, deeply 
entrenched beliefs and biases regarding optimal PDA care exist. Many health care 
providers lack sufficient equipoise to support the conduct of robust, clinical trials.  
Liebowitz et. al. described that, in the PDA TOLERATE Trial, 152 potentially eligible 
infants were not recruited and received treatment of their PDA outside the trial due to 
lack of physician equipoise.8  In the absence of consensus on optimal treatment 
practices, health care providers are encouraged to support patient enrollment into 
clinical studies.2 Even if health care providers are willing to participate, 
parents/caregivers may be reluctant to provide consent. Differences between enrolled 
versus eligible but not enrolled infants, limit the external validity of study findings. 
Innovative qualitative research from adult studies has shown that clear and transparent 
discussions of the risks and benefits of treatment options, appropriately oriented to 
participants, can markedly increase consent rates in RCTs comparing intervention 
versus non-intervention arms.9  Lack of formal training in the processes necessary to 
obtain parental consent, particularly for studies involving complex interventions among 
high-risk patient populations, also contribute to low rates of study consent. Strategies to 
support health care providers to effectively present high quality information and 
communicate successfully with adult patients have been developed,10 but would need 
adapting for pediatric trials. Novel trial designs, such as comprehensive-cohorts, that 
incorporate parallel follow-up for caregivers who refuse randomization, can provide 
valuable observational data on outcomes to increase generalizability. Finally, evidence 
is growing on the importance of incorporating family-centered outcomes into proposed 
trials, with the goal of better understanding the impact these interventions have on 
caregivers.  
A number of considerations in the design of contemporary, pragmatic trials on 
PDA management are warranted. Infants who fail early treatment and continue to have 
clinical and hemodynamic sequelae potentially attributable to the ductus are at the crux 
of the medical debate. These infants, beyond the window when drug therapy is typically 
used and spontaneous closure has yet to occur, represent an ongoing therapeutic 
dilemma for health care providers. In trials incorporating catheter-based closure, 
prioritization of this high-risk subgroup is paramount. Second, previous PDA trials are 
limited because of high rates of open label treatments in control (non-intervention) 
groups. To adequately explore if differences in the duration of PDA exposure contribute 
to adverse outcomes, rescue criteria in the control arm of RCTs should be carefully 
designed so they are infrequently used and consistently applied.     
The practice of catheter-based PDA closure among premature infants has not 
been adequately compared to alternative treatment strategies, leaving health care 
providers without evidence-based data to guide clinical decision making. This reinforces 
the need for a well-designed, RCT. New strategies to increase the quality and efficiency 
of clinical studies on PDA management must be considered. Without high-quality 
randomized studies, the debate of how best to care for infants following failed early 
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